Aligos posts results for ALG-097558 renal impairment PK study, trial completed
Aligos Therapeutics' Phase 1 study of ALG-097558 in renal impairment posted results, with the trial marked completed after enrolling 12 participants.
Aligos Therapeutics had one clinical trial update this week, a results posting for its COVID-19 antiviral candidate.
- ALG-097558, an oral antiviral in Phase 1, had trial results posted for "NCT06698549," a study of subjects with severe renal impairment versus normal renal function. The study is a non-randomized, interventional Phase 1 trial with an enrollment of 12 participants (actual).1 The trial is sponsored by Aligos Therapeutics, with the National Institute of Allergy and Infectious Diseases (NIAID) as a collaborator.1 Subjects with severe renal impairment received oral doses of 300 mg ALG-097558 twice daily for 6 days for 11 total doses.1 The study's overall status is completed, with primary completion on 2025-07-23 and results first posted on 2026-07-09.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.